C-VGB3

O=C(N[C@@H](CSSC[C@@H](C(O)=O)NC1=O)C(N[C@@H](CCCNC(N)=N)C(N2[C@@H](CCC2)C(N3[C@@H](CCC3)C(N[C@@H](CC(O)=O)C(N[C@@H](CC(O)=O)C(NCC(N[C@H]1CC(C)C)=O)=O)=O)=O)=O)=O)=O)[C@H](CCC(O)=O)N

[1]Namjoo M, et al. A VEGFB-Based Peptidomimetic Inhibits VEGFR2-Mediated PI3K/Akt/mTOR and PLCγ/ERK Signaling and Elicits Apoptotic, Antiangiogenic, and Antitumor Activities. Pharmaceuticals (Basel) . 2023 Jun 20;16 (6) :906.|[2]Sadremomtaz A, et al. Molecular docking, synthesis and biological evaluation of Vascular Endothelial Growth Factor (VEGF) B based peptide as antiangiogenic agent targeting the second domain of the Vascular Endothelial Growth Factor Receptor 1 (VEGFR1D2) for anticancer application. Signal Transduct Target Ther. 2020 Jun 5;5 (1) :76.